| Drug Name |
Cabazitaxel |
| Drug ID |
BADD_D00328 |
| Description |
Cabazitaxel is an anti-neoplastic used with the steroid medicine prednisone. Cabazitaxel is used to treat people with prostate cancer that has progressed despite treatment with docetaxel. Cabazitaxel is prepared by semi-synthesis with a precursor extracted from yew needles (10-deacetylbaccatin III). It was approved by the U.S. Food and Drug Administration (FDA) on June 17, 2010. |
| Indications and Usage |
For treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing treatment regimen. |
| Marketing Status |
approved |
| ATC Code |
L01CD04 |
| DrugBank ID |
DB06772
|
| KEGG ID |
D09755
|
| MeSH ID |
C552428
|
| PubChem ID |
9854073
|
| TTD Drug ID |
D02HSB
|
| NDC Product Code |
54893-0016; 61200-101; 0024-5824; 47848-044; 63126-909; 55111-962; 68554-0080 |
| UNII |
51F690397J
|
| Synonyms |
cabazitaxel | kabazitaxel | Jevtana |
